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Aromataseexcesssyndrome(AEXS)isarareautosomaldominantdisordercharacterizedbygynecomastia.Thisconditioniscaused
by overexpression of CYP19A1 encoding aromatase, and three types of cryptic genomic rearrangement around CYP19A1,t h a ti s ,
duplications,deletions,andinversions,havebeenidentiﬁedinAEXS.DuplicationsappeartohavecausedCYP19A1overexpression
because of an increased number of physiological promoters, whereas deletions and inversions would have induced wide CYP19A1
expression due to the formation of chimeric genes consisting of a noncoding exon(s) of a neighboring gene and CYP19A1 coding
exons.Genotype-phenotypeanalysisimpliesthatphenotypicseverityofAEXSisprimarilydeterminedbytheexpressionpatternof
CYP19A1 and the chimeric genes and by the structural property of the fused exons with a promoter function (i.e., the presence or
the absence of a natural translation start codon). These results provide novel information about molecular mechanisms of human
genetic disorders and biological function of estrogens.
1.Introduction
Aromatase encoded by CYP19A1 is a cytochrome P450 en-
zyme that plays a key role in estrogen biosynthesis [1]. It
catalyzes the conversion of Δ4-androstendione into estrone
(E1) and that of testosterone (T) into estradiol (E2) in the
placenta and ovary as well as in other tissues such as the fat,
skin, bone, and brain [1].
Overexpression of CYP19A1 causes a rare autosomal
dominant disorder referred to as aromatase excess syndrome
(AEXS, OMIM no. 139300) [2–8]. AEXS is characterized by
pre- or peripubertal onset gynecomastia, gonadal dysfunc-
tion, advanced bone age from childhood to pubertal period,
and short adult height in aﬀected males [2–8]. In particular,
gynecomastia is a salient feature in AEXS, and, therefore,
this condition is also known as hereditary gynecomastia or
familial gynecomastia [5]. Aﬀected females may also show
several clinical features such as macromastia, precocious
puberty, irregular menses, and short adult height [5, 6, 8].
Recently, three types of cryptic genomic rearrangements
around CYP19A1 have been identiﬁed in 23 male patients
withAEXS[2–4].Theresultsprovideusefulimplications not
only for the clariﬁcation of underlying mechanisms but also
for the identiﬁcation of phenotypic determinants. Here, we
review the current knowledge about AEXS.
2. The AromataseGene(CYP19A1)
CYP19A1 encoding aromatase is located on 15q21.2 adjacent
to DMXL2and GLDN (Figure 1)[3,9].Itspans ∼123kband
consists of at least 11 noncoding exons 1 and nine coding
exons 2–10 [9–12]. Each exon 1 is accompanied by a tissue-
speciﬁc promoter and is spliced alternatively onto a common
splice acceptor site at exon 2, although some transcripts
are known to contain two of the exons 1 probably due to
a splice error [9–11]. Transcription of CYP19A1 appears
to be tightly regulated by alternative usage of the multiple2 International Journal of Endocrinology
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Figure 1: Simpliﬁed schematic representation indicating the genomic structure of CYP19A1. CYP19A1 is located on 15q21.2 adjacent to
DMXL2 and GLDN and consists of at least 11 noncoding exons 1 and nine coding exons 2–10 [9, 10]. Each exon 1 is accompanied by a
tissue-speciﬁc promoter and is spliced alternatively onto a common splice acceptor site at exon 2 [9–13].
promoters[9–13].Actually,CYP19A1isstronglyexpressedin
the placenta and moderately expressed in the ovary, whereas
it is only weakly expressed in a rather limited number of
tissues including skin, fat, and hypothalamus [4, 13]. Of the
11 noncoding exons 1, exon I.4 seems to play a critical role in
the regulation of estrogen biosynthesis in males, because this
exon contains the major promoter for extragonadal tissues
[9, 10].
3. Molecular Bases of AEXS
A family with dominantly transmitted gynecomastia of pre-
pubertal onset was ﬁrst described in 1962 by Wallach and
Garcia [14]. After this initial report, several cases have been
described [5–8, 15]. Laboratory examinations of the aﬀected
males revealed markedly elevated serum estrogen values
and estrogen/androgen ratios and signiﬁcantly increased
aromatase activity in ﬁbroblasts and lymphocytes [5–8, 15].
Linkage analyses in two families indicated a close association
between CYP19A1-ﬂanking polymorphic markers and the
diseasephenotype[5,6].Thus,theconditionwasassumedto
be caused by gain-of-function mutations of CYP19A1, and,
therefore, the name of AEXS was coined for this condition
[7, 8]. However, since direct sequencing and Southern
blotting analysis failed to detect mutations or copy number
abnormalities in the coding region of CYP19A1 [5, 6], the
molecular basis of this entity remained elusive until recently.
In 2003, Shozu et al. reported a father-son pair and a
sporadic case with AEXS in whom they identiﬁed heterozy-
gous chromosomal inversions of the chromosome 15 [2].
Subsequently, Demura et al. performed detailed molecular
studies for these cases and additional two cases and char-
acterized four types of inversions aﬀecting the 5  region of
CYP19A1 [3]. Each inversion has resulted in the formation
of a chimeric gene consisting of CYP19A1 coding exons
and exon 1 of the widely expressed neighboring genes,
that is, CGNL1, TMOD3, MAPK6, and TLN2. These data
imply that overexpression of CYP19A1 in the inversion-
positive cases are caused by cryptic usage of constitutively
active promoters. Consistent with this, in silico analysis
revealed the presence of promoter-compatible sequences
around exon 1 of CGN1, TMOD3,a n dMAPK6 in multiple
cell types, although such sequences remain to be identiﬁed
for noncoding exons of TLN2 [4].
Werecentlystudied18malesfromsixfamilieswithAEXS
(families A–F) and identiﬁed three types of heterozygous
cryptic genomic rearrangements in the upstream region of
the CYP19A1 coding exons (Figure 2)[ 4]. In families A
and B, we identiﬁed the same 79,156bp tandem duplica-
tion encompassing seven of the 11 noncoding exons 1 of
CYP19A1. Notably, this duplication includes exon I.4 that
functions as a major promoter for extragonadal tissues such
as fat and skin; therefore, CYP19A1 overexpression in these
families would be explained by increasing the number of
this promoter. Indeed, RT-PCR analysis detected a splice
variant consisting of exon I.4 at the 5  side and exon I.8 at
the 3  side in lymphoblastoid cell lines and skin ﬁbroblasts
of the patients, indicating that the duplicated exon I.4
at the distal nonphysiological position actually functions
as transcription start sites. In family C, we identiﬁed a
211,631bp deletion aﬀecting exons 2–43 of DMXL2 and
exons 5–10 of GLDN. This deletion appears to have caused
CYP19A1 overexpression because of cryptic usage of DMXL2
exon 1 as an extra transcription start site for CYP19A1.
Indeed, RT-PCR revealed the presence of chimeric mRNA
clones consisting of DMXL2 exon 1 and CYP19A1 exon 2,
supporting the notion that aberrant splicing has occurred
between these two exons. Such DMXL2/CYP19A1 chimeric
mRNA accounted for 2–5% of CYP19A1-containing tran-
scripts from skin ﬁbroblasts. In families D–F, we identiﬁedInternational Journal of Endocrinology 3
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Figure 2: Schematic representation of duplications and deletions identiﬁed in patients with AEXS. (a) the tandem duplication of families A
and B [4]. Genome: the duplication (yellow boxes) includes seven of the 11 noncoding exons 1 of CYP19A1. mRNA: the sequence of a rare
transcript is shown. The 3 -end of exon I.4 is connected with the 5 -end of exon I.8. (b) The deletion of family C [4]. Genome: the deletion
(a gray area) includes exons 2–43 of DMXL2 and exons 5–10 of GLDN. mRNA: The sequence of a rare chimeric gene transcript is shown.
DMXL2 exon 1 consisting of a noncoding region and a coding region is spliced onto the common acceptor site of CYP19A1 exon 2. (c) The
deletion of families D–F [4]. Genome: the deletion (a gray area) includes exons 2–43 of DMXL2. mRNA: the sequence of a rare chimeric
gene transcript is delineated. The mRNA structure is the same as that detected in family C.
an identical 165,901bp deletion including exons 2–43 of
DMXL2.RT-PCRidentiﬁedthesamechimericmRNAasthat
detected in family C.
Collectively, three types of genomic rearrangements on
15q21 have been identiﬁed in AEXS to date, namely, inver-
sion type (four subtypes), duplication type, and deletion
type (two subtypes) (Figure 3(a)) [2–4]. In this regard,
sequence analyses for the breakpoints have indicated that (1)
inversion types are formed by a repeat sequence-mediated
nonallelicintrachromosomalorinterchromosomalrecombi-
nation or by a replication-based mechanism of fork stalling
and template switching (FoSTeS) that occurs in the absence
ofrepeatsequencesandisoftenassociatedwithmicrohomol-
ogy [16], (2) duplication type is generated by FoSTeS, and
(3) deletions are produced by nonhomologous end joining
that takes place between nonhomologous sequences and is
frequently accompanied by an insertion of a short segment
at the fusion point or by a nonallelic recombination [16].4 International Journal of Endocrinology
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Figure 3: Structural and functional properties of the fused exons. (a) Schematic representation of the rearranged genome and mRNA
structures. The white and the black boxes of CYP19A1 exon 2 show untranslated region and coding region, respectively. For genome, the
striped and the painted arrows indicate noncoding and coding exons, respectively (5  →3 ). The inverted genomic regions are delineated
in blue lines. For mRNA, colored striped boxes represent noncoding regions of each gene. The DMXL2-CYP19A1 chimeric mRNA has
two translation initiation codons and therefore is destined to produce not only CYP19A1 protein but also a 47 amino acid protein which
is predicted to undergo nonsense-mediated mRNA decay (NMD). The deletion and the inversion types are associated with heterozygous
impairment of neighboring genes (deletion or disconnection between noncoding exon(s) and the following coding exons). The inversion
subtype 1 is accompanied by inversion of eight of the 11 CYP19A1 exons 1, and the inversion subtype 2 is associated with inversion of
the placenta-speciﬁc CYP19A1 exon I.1. (b) Expression patterns of CYP19A1 and the ﬁve neighboring genes involved in the chimeric gene
formation [4]. Relative mRNA levels against TBP in normal human tissues are shown.
Thus, it appears that genomic sequence around CYP19A1
harbors particular motifs that are vulnerable to replication-
and recombination-mediated errors. The results provide
novel mechanisms of gain-of-function mutations leading to
human diseases.
4. ClinicalFeaturesof AEXS
To date, a total of 23 male cases from 10 families have
been reported to have molecularly conﬁrmed AEXS (Table 1,
Figure 3(a)) [2–4]. They exhibited pre- or peripubertal onsetInternational Journal of Endocrinology 5
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gynecomastia, small testes with fairly preserved masculin-
ization, obvious or relative tall stature in childhood and
grossly normal or apparent short stature in adulthood,
and age-appropriate or variably advanced bone ages. Blood
endocrine studies revealed markedly elevated E1 values and
E2/T ratios in all cases examined and normal or variably
elevated E2 values. In addition, Δ4-androstenedione, T,
and dihydrotestosterone values were low or normal, and
human chorionic gonadotropin (hCG) test indicated normal
T responses. Notably, LH values were grossly normal at
the baseline and variably responded to GnRH stimulation,
whereas FSH values were low at the baseline and poorly
responded to GnRH stimulation even after preceding GnRH
priming, in all cases examined.
The severity of such clinical phenotypes is primarily de-
pendent on the underlying mechanisms (Table 1). They are
obviously mild in the duplication type, moderate in the
deletion type, and severe in the inversion type, except for
serum FSH values that remain suppressed irrespective of the
underlying mechanisms. Likewise, gynecomastia has been
reported to be ameliorated with 1mg/day of aromatase
inhibitor (anastrozole) in the duplication and the deletion
types and with 2–4mg/day of anastrozole in the inversion
type [4].
5. ExpressionPattern of CYP19A1 and
the Chimeric Genes as
One PhenotypicDeterminant
Phenotypic severity is much milder in the duplication type
than in the deletion and the inversion types. This would
be explained by the tissue expression pattern of CYP19A1
and the chimeric genes. Indeed, RT-PCR analysis using
normal human tissue samples revealed that CYP19A1 is
expressed only in a limited number of tissues such as
placenta, ovary, skin, and fat, while the ﬁve genes involved
in the formation of chimeric genes are widely expressed with
some degree of variation (Figure 3(b)). Therefore, it is likely
that the duplication types would simply increase CYP19A1
transcription in native CYP19A1-expressing tissues, whereas
the deletion and the inversion types lead to CYP19A1
overexpression in a range of tissues, because expression
patterns of chimeric genes are predicted to follow those of
the original genes. Furthermore, it is also likely that the
native CYP19A1 promoter is subject to negative feedback
by elevated estrogens [17], whereas such negative feedback
eﬀect by estrogen is weak or even absent for the chimeric
genes in the deletion and the inversion types.
6. StructuralPropertyof the FusedExons as
Another PhenotypicDeterminant
Phenotypic severity is also milder in the deletion type than
in the inversion types, despite a similar wide expression
pattern of genes involved in the chimeric gene formation
(Table 1, Figure 3(b)). In this context, it is noteworthy that
a translation start codon and a following coding region
are present on exon 1 of DMXL2 of the deletion type but
not on exons 1 of the chimeric genes of the inversion
types (Figure 3(a)). Thus, it is likely that DMXL2/CYP19A1
chimeric mRNAs transcribed by the DMXL2 promoter
preferentially recognize the natural start codon on DMXL2
exon 1 and undergo nonsense-mediated mRNA decay and
that rather exceptional chimeric mRNAs, which recognize
the start codon on CYP19A1 exon 2, are transcribed into
CYP19A1 protein. By contrast, such a phenomenon would
not be postulated for the inversion-mediated chimeric
mRNAs. Consistent with this, it has been shown that the
DMXL2/CYP19A1 chimeric mRNA is present only in 2–
5% of CYP19A1-containing transcripts from skin ﬁbroblasts,
whereas the CGNL1/CYP19A1 chimeric mRNA and the
TMOD3/CYP19A1 chimeric mRNA account for 89–100%
and 80% of transcripts from skin ﬁbroblasts, respectively
[2, 4].
In addition, the genomic structure caused by the rear-
rangements would aﬀect eﬃciency of splicing between non-
coding exon(s) of neighboring genes and CYP19A1 exon 2.
Forexample,intheinversionsubtype1,thephysicaldistance
between CGNL1 e x o n1a n dCYP19A1 exon 2 is short, and,
while a splice competition may be possible between exon 1 of
neighboring genes and original CYP19A1 exons 1, eight of 11
CYP19A1 exons 1 including exon I.4 have been disconnected
from CYP19A1 coding exons by inversion (Figure 3(a)). This
may also enhance the splicing eﬃciency between CGNL1
exon 1 and CYP19A1 exon 2 and thereby lead to relatively
severe overexpression of the CGNL1-CYP19A1 chimeric
gene, although this hypothesis would not be applicable for
other chimeric genes.
7. Implication for
the Hypothalamus-Pituitary-Gonadal
Axis Function
It is notable that a similar degree of FSH-dominant hypog-
onadotropic hypogonadism is observed in the three types,
although E1 and E2 values and E2/T ratios are much higher
in the inversion type than in the duplication and deletion
types (Table 1). In particular, FSH was severely suppressed
even after GnRH priming in the duplication type [4]. This
implies that a relatively mild excess of circulatory estrogens
can exert a strong negative feedback eﬀect on FSH secretion
primarily at the pituitary. This would be consistent with
the results of animal studies that show strong inhibitory
eﬀect of E2 on transcription of FSH beta-subunit gene in the
pituitary cells and almost negligible eﬀect on synthesis of LH
beta-subunit and secretion of LH [18, 19]. In this regard,
while T responses to hCG stimulation are normal in the
duplication and the deletion types and somewhat low in the
inversion type, this would be consistent with fairly preserved
LH secretion in the three types and markedly increased
estrogen values in the inversion type. In addition, whereas
fertility and spermatogenesis are normally preserved in the
three types, this would be explained by the FSH-dominant
hypogonadotropic hypogonadism, because FSH plays only a
minor role in male fertility (spermatogenesis) [20].8 International Journal of Endocrinology
8. Conclusions
Current studies argue that AEXS is caused by overexpression
of CYP19A1 due to three diﬀerent types of cryptic genomic
rearrangements including duplications, deletions, and inver-
sions. It seems that transcriptional activity and structural
property of the fused promoter constitutes the underlying
factor for the clinical variability in most features of AEXS
exceptforFSH-dominanthypogonadotropichypogonadism.
Thus, AEXS represents a novel model for gain-of-function
mutation leading to human genetic disorders.
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